Summary
The effects of calcium antagonists on psychological well-being, cognitive function, activity and physical symptoms in hypertensive patients are reviewed. Effects on these aspects of quality of life appear to differ according to whether a dihydropyridine calcium antagonist such as nifedipine is employed or verapamil, which is a phenylalkylamine derivative. Nifedipine has been associated with a self-assessment of impaired cognitive function in 2 clinical trials. Nifedipine was also associated with more symptomatic complaints than both atenolol and verapamil in different studies. The problems with nifedipine centred on oedema, flushing and palpitations. Verapamil was associated with constipation.
Compared with other classes of antihypertensive drugs, the position of calcium antagonists with respect to the maintenance of patients’ quality of life is presently unclear. Verapamil has been associated with improved quality of life compared with propranolol (a β-blocker) and nifedipine. Verapamil appears to have similar effects on quality of life as atenolol and the angiotensin converting enzyme (ACE) inhibitor, captopril. The position of nifedipine remains unclear.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta blockers. Journal of the American Medical Association 255: 357–360, 1986
Borland C, Amadi A, Murphy P, Shallcross T. Biochemical and clinical correlates of diuretic therapy in the elderly. Age and Ageing 15: 357–363, 1986
Bulpitt CJ, Fletcher AE. The measurement of quality of life in hypertensive patients: a practical approach. British Journal of Clinical Pharmacology 30: 353–364, 1990
Bulpitt CJ, Fletcher AE. Quality of life evaluation of antihypertensive drugs. Pharmaco Economics 1(2): 95–102, 1992
Callender JS, Medley IR, Robertson JIS. Psychological effects of nicardipine and propranolol on hypertensive patients. British Journal of Clinical Pharmacology 22: 267S–272S, 1986
Croog SH, Kong BW, Levine S, Weir MR, Baume RM, et al. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Archives of Internal Medicine 150: 1733–1741, 1990
Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 314: 1657–1664, 1986
Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension: a review. Hypertension 13: 136–144, 1989
Fitzsimons TJ. Calcium antagonists: a review of the recent comparative trials. Journal of Hypertension 5: S11–S15, 1987
Fletcher AE, Battersby C, Bulpitt CJ, on behalf of the European Pinacidil Study Group. Quality of life on hypertensive treatment: results from a randomised double blind trial of pinacidil and nifedipine. Abstract No. 262, European Society of Hypertension, Milan, 1989b
Fletcher AE, Chester PC, Hawkins CMA, Latham AN, Pike LA, et al. The effects of verapamil and propranolol on quality of life in hypertension. Journal of Human Hypertension 3: 125–130, 1989a
Giannini AJ, Houser WL, Loiselle RH, Giannini MC, Price WA. Antimanic effects of verapamil. American Journal of Psychiatry 141: 1602–1603, 1984
Gilchrist NL, Nicholls MG, Ewer TC, Livesey JH, Sainsbury R. A comparison of long acting nifedipine and enalapril in elderly hypertensives: a randomised single blind cross over study. Journal of Human Hypertension 2: 33–39, 1988
Grebb JA. Nifedipine and flunarizine block amphetamine induced behavioural stimulation in mice. Life Sciences 38: 2375–2381, 1986
Halperin AK, Cubeddu LX. The role of calcium channel blockers in the treatment of hypertension. American Heart Journal 111: 363–382, 1986
Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine induced calcium channel blockade. American Journal of Psychiatry 10: 1277–1299, 1988
Kumar KL, Hodges M. Disturbing dreams with long acting verapamil. New England Journal of Medicine 318: 929–930, 1988
MacLennan WJ. Diuretics in the elderly: how safe? British Medical Journal 296: 1551, 1988
McDevitt DG, Currie D, Nicholson AN, Wright NA, Zetlein MB. Central effects of the calcium antagonist, nifedipine. British Journal of Clinical Pharmacology 32: 541–549, 1991
Medical Research Council Working Party on Mild to Moderate Hypertension. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539–543, 1981
Nifedipine-Atenolol Study Review Committee. Nifedipine and atenolol singly and combined for treatment of essential hypertension: comparative multicentre study in general practice in the United Kingdom. British Medical Journal 296: 468–472, 1988
Otten H, Schmieder R, Ruddel H. Disparate effects of initial anti-hypertensive therapy on well being. Journal of Hypertension 5(Suppl. 1): S37–S40, 1987
Overweg J, Binnie CD, Meijer JW, Meinardi H, Nuijten ST, et al. Double blind placebo controlled trial of flunarizine as add on therapy in epilepsy. Epilepsia 25: 217–222, 1984
Palat GK, Hooker EA, Movahed A. Secondary mania associated with diltiazem. Clinical Cardiology 7: 611–612, 1984
Palmer A, Fletcher A, Hamilton G, Muriss S, Bulpitt C. A comparison of verapamil and nifedipine on quality of life. British Journal of Clinical Pharmacology 30: 365–370, 1990
Patterson Russell R. Side effects of calcium channel blockers. Hypertension 11: 1142–1144, 1988
Solomon S, Hotchkiss E, Saravay SM, Bayer C, Ramsey P, et al. Impairment of memory by antihypertensive medication. Archives of General Psychiatry 40: 1109–1112, 1983
Zachariah PK. Quality of life with antihypertensive medication. Journal of Hypertension 5: S105–S110, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fletcher, A., Bulpitt, C. Quality of Life in the Treatment of Hypertension. Drugs 44 (Suppl 1), 135–140 (1992). https://doi.org/10.2165/00003495-199200441-00026
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199200441-00026